Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Accupac, Llc
EIR
•Accupac, Llc•March 19, 2019

Accupac, Llc – FDA EIR, Mar 19, 2019

Record Details

An FDA inspection of Accupac, Inc., a contract manufacturer of OTC drugs, medical devices, and cosmetics in Lakewood, NJ, took place from February 26 to March 19, 2019. The inspection evaluated compliance with Current Good Manufacturing Practices (cGMP) for drugs and medical device manufacturing regulations. A five-point FDA Form 483 was issued, highlighting significant deficiencies. For drug products, observations included inadequate documentation in batch production records, specifically failing to record critical steps such as the accurate addition of active ingredients in products like Zicam Extreme Congestion Relief Gel. Laboratory control systems were also cited; investigations into unexplained discrepancies (Out-of-Specification results) lacked complete conclusions and follow-up, with proposed corrective and preventative actions (CAPAs) not being implemented. Furthermore, instrument calibration procedures were not consistently adhered to, resulting in balances being used for measurements outside their calibrated ranges, affecting products like CeraVe Hydrocortisone Cream. Regarding medical devices, particularly Cidex OPA, Accupac's corrective and preventive action procedures were found to be insufficient. Multiple customer complaints about foreign material in Cidex OPA solutions lacked proper CAPA initiation, follow-up, or identification of particle origin. Additionally, complaints concerning potential device failure, labeling, or packaging issues were not thoroughly reviewed, evaluated, or investigated, with inadequate documentation to support root causes or visual inspection findings. Accupac management received the FDA Form 483 and verbally committed to addressing the observations, noting a "promise to correct" for the device-related issues. A comprehensive written response is formally required by the FDA within 15 working days.

Company
Accupac, Llc
Inspection date
March 19, 2019
Product type
drugs
Office
New Jersey District Office
People
  • Mark Hebda (company_representative)
  • Steven Alexander (company_representative)
  • Nena Wilks (company_representative)
  • Brian Hall (company_representative)
  • Mark Hinkel (company_representative)
View Company Profile

ID · b9568c42-c81d-45fc-b785-24c0e62f9eb3

Violation Codes3
21 CFR 820.19821 CFR 80321 CFR 820.50

Full citation text and observation details available on the Dashboard.

Other documents for Accupac, Llc
  • 483 - 2026-02-13February 13, 2026
  • 483 - 2021-11-18November 18, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Accupac, Llc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.